Colorectal cancer (CRC) is the third most common malignancy globally, with microsatellite instability (MSI) present in approximately 15% of cases. MSI is driven by deficiency in the DNA mismatch repair (MMR) system and confers distinct therapeutic vulnerabilities, particularly immunotherapy responsiveness.
Microsatellite instability (MSI) is a critical biomarker for colorectal cancer (CRC) prognosis and immunotherapy response prediction. Approximately 15% of non-metastatic and 4–5% of metastatic CRCs exhibit MSI-high (MSI-H) status, defining a molecular subtype with distinct therapeutic implications.
Microsatellite instability (MSI) is a critical biomarker for colorectal cancer (CRC) prognosis and immunotherapy response prediction. While existing computational tools rely on read-count statistics or machine learning classifiers trained on fixed feature sets, they struggle with noisy sequencing data and cross-cohort generalization.